G6PD Deficiency in the COVID-19 Pandemic

There are about 350 million people with glucose-6-phosphate dehydrogenase (G6PD) deficiency worldwide.

In this letter, Al-Abdi discusses why G6PD deficiency can be a challenge during the COVID‐19 pandemic. If hydroxychloroquine is found to be the silver bullet for COVID‐19, then this may be a big challenge in treating COVID‐19 in G6PD-deficient patients. Accordingly, it is prudent to use additional precautionary measures to prevent COVID-19 from reaching G6PD-deficient individuals.

Authors: Sameer Al-Abdi, Maryam Al-Aamri

G6PD deficiency in the COVID-19 pandemic: ‘‘Ghost within Ghost’’, Hematol Oncol Stem Cell Ther, https://doi.org/10.1016/j.hemonc.2020.04.002Related resources:

Baebies Announces CE Mark for FINDER, an Innovative Near-Patient Testing Platform for Glucose-6-Phosphate Dehydrogenase (press release)

There are about 350 million people with glucose-6-phosphate dehydrogenase (G6PD) deficiency worldwide.
In this letter, Al-Abdi discusses why G6PD deficiency can be a challenge during the COVID‐19 pandemic. If hydroxychloroquine is found to be the silver bullet for COVID‐19, then this may be a big challenge in treating COVID‐19 in G6PD-deficient patients. Accordingly, it is prudent to use additional precautionary measures to prevent COVID-19 from reaching G6PD-deficient individuals.
Authors: Sameer Al-Abdi, Maryam Al-Aamri
G6PD deficiency in the COVID-19 pandemic: ‘‘Ghost within Ghost’’, Hematol Oncol Stem Cell Ther